|
Gene: SLC14A2 |
Gene summary for SLC14A2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC14A2 | Gene ID | 8170 |
Gene name | solute carrier family 14 member 2 | |
Gene Alias | HUT2 | |
Cytomap | 18q12.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q15849 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8170 | SLC14A2 | HCC1 | Human | Liver | HCC | 2.28e-17 | 1.50e+00 | 0.5336 |
8170 | SLC14A2 | HCC2 | Human | Liver | HCC | 6.04e-30 | 1.60e+00 | 0.5341 |
8170 | SLC14A2 | HCC5 | Human | Liver | HCC | 1.94e-30 | 1.81e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | |
Breast | IDC | |
Breast | DCIS | |
Cervix | CC | |
Cervix | HSIL_HPV |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC14A2 | SNV | Missense_Mutation | rs774147660 | c.1946T>G | p.Val649Gly | p.V649G | Q15849 | protein_coding | deleterious(0) | possibly_damaging(0.552) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
SLC14A2 | SNV | Missense_Mutation | novel | c.1740N>A | p.Phe580Leu | p.F580L | Q15849 | protein_coding | tolerated(0.49) | benign(0.242) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC14A2 | SNV | Missense_Mutation | rs368161253 | c.2752N>A | p.Asp918Asn | p.D918N | Q15849 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.454) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC14A2 | SNV | Missense_Mutation | rs774147660 | c.1946N>G | p.Val649Gly | p.V649G | Q15849 | protein_coding | deleterious(0) | possibly_damaging(0.552) | TCGA-AO-A1KP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
SLC14A2 | SNV | Missense_Mutation | novel | c.1708N>A | p.Gly570Arg | p.G570R | Q15849 | protein_coding | deleterious(0.04) | benign(0) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
SLC14A2 | SNV | Missense_Mutation | rs774147660 | c.1946N>G | p.Val649Gly | p.V649G | Q15849 | protein_coding | deleterious(0) | possibly_damaging(0.552) | TCGA-E9-A22A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
SLC14A2 | insertion | Nonsense_Mutation | novel | c.290_291insGTGGCTGTGACCCGAAGGAATGTCTGACCCCCACAGCAGT | p.Tyr97Ter | p.Y97* | Q15849 | protein_coding | TCGA-A2-A0ER-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
SLC14A2 | SNV | Missense_Mutation | rs765462494 | c.2506N>A | p.Ala836Thr | p.A836T | Q15849 | protein_coding | tolerated(0.25) | benign(0.274) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC14A2 | SNV | Missense_Mutation | c.1224C>G | p.Ile408Met | p.I408M | Q15849 | protein_coding | tolerated(0.08) | benign(0.422) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC14A2 | SNV | Missense_Mutation | c.1705G>A | p.Glu569Lys | p.E569K | Q15849 | protein_coding | tolerated(0.79) | benign(0.003) | TCGA-VS-A8QA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8170 | SLC14A2 | TRANSPORTER | nifedipine | NIFEDIPINE | 17344938 |
Page: 1 |